natgillin/translations-raw huggingface dataset:
Den Europæiske Unions Domstol fastslog i sin dom af 16. april 2015 i de forenede sager C-317/13 og sag C-679/13 [3], at Rådet skal høre Europa-Parlamentet inden vedtagelsen af gennemførelsesafgørelser i medfør af artikel 8, stk. 3, i afgørelse 2005/387/RIA.
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Rådets gennemførelsesafgørelse 2014/688/EU [4] blev vedtaget uden en sådan forudgående høring og er derfor behæftet med en procedurefejl.
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 25I-NBOMe, AH-7921, MDPV and methoxetamine under control across the Union.
Afgørelse 2014/688/EU bør derfor erstattes af nærværende afgørelse.
In its judgment of 16 April 2015 in Joined Cases C-317/13 and C-679/13 [3], the Court of Justice of the European Union held that prior to adopting an implementing decision on the basis of Article 8(3) of Decision 2005/387/JHA, the Council should consult the European Parliament.
Med henblik på at sikre kontinuiteten af kontrolforanstaltningerne i hele Unionen samt overholdelsen af medlemsstaternes forpligtelser i henhold til De Forenede Nationers konvention af 1971 om psykotrope stoffer og De Forenede Nationers enkeltkonvention af 1961 angående narkotiske midler med hensyn til 4-iod-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamin (25I-NBOMe), 3,4-dichlor-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamid (AH-7921), 3,4-methylendioxypyrovaleron (MDPV) og 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanon (methoxetamin) bør nærværende afgørelse ikke berøre medlemsstaternes forpligtelser med hensyn til fristen for at underkaste disse nye psykoaktive stoffer kontrolforanstaltninger og strafferetlige sanktioner i deres nationale lovgivning som fastsat i artikel 2 i afgørelse 2014/688/EU.
Council Implementing Decision 2014/688/EU [4] was adopted without such prior consultation and consequently is vitiated by a procedural defect.
Afgørelse 2005/387/RIA er bindende for Danmark, som derfor deltager i vedtagelsen og anvendelsen af denne afgørelse, der gennemfører afgørelse 2005/387/RIA.
Decision 2014/688/EU should, therefore, be replaced by this Decision.
Afgørelse 2005/387/RIA er bindende for Irland, som derfor deltager i vedtagelsen og anvendelsen af denne afgørelse, der gennemfører afgørelse 2005/387/RIA.
In order to ensure the continuity of control measures across the Union, as well as of the compliance with the obligations of the Member States under the 1971 United Nations Convention on Psychotropic Substances and under the 1961 United Nations Single Convention on Narcotic Drugs with regard to 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), this Decision should be without prejudice to the obligations of the Member States relating to the time limit for subjecting those new psychoactive substances to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2014/688/EU.
Afgørelse 2005/387/RIA er ikke bindende for Det Forenede Kongerige, som derfor ikke deltager i vedtagelsen af denne afgørelse, som gennemfører afgørelse 2005/387/RIA, og som ikke er bindende for og ikke finder anvendelse i Det Forenede Kongerige —
Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
VEDTAGET DENNE AFGØRELSE:
Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Artikel 1
The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision which implements Decision 2005/387/JHA and is not bound by it or subject to its application,
Følgende nye psykoaktive stoffer underkastes kontrolforanstaltninger i hele Unionen:
HAS ADOPTED THIS DECISION:
od-2,5-dimethoxy-N-(2-methoxybenzyl)-phenethylamin (25I-NBOMe)
Article 1
3,4-dichlor-N-[[1-dimethylamino)-cyclohexyl]methyl]-benzamid (AH-7921)
The following new psychoactive substances shall be subjected to control measures across the Union:
3,4-methylendioxypyrovaleron (MDPV)
odo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe);
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanon (methoxetamin).
3,4-dichloro-N-[[1-dimethylamino)cyclohexyl]methyl]benzamide (AH-7921);
Artikel 2
3,4-methylenedioxypyrovalerone (MDPV);
Afgørelse 2014/688/EU erstattes, uden at dette berører medlemsstaternes forpligtelser med hensyn til fristen for at underkaste 4-iod-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamin (25I-NBOMe), 3,4-dichlor-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamid (AH-7921), 3,4-methylendioxypyrovaleron (MDPV) og 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanon (methoxetamin) kontrolforanstaltninger og strafferetlige sanktioner i deres nationale lovgivning som fastsat i artikel 2 i afgørelse 2014/688/EU.
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine).
Denne afgørelse træder i kraft dagen efter offentliggørelsen i Den Europæiske Unions Tidende.
Decision 2014/688/EU is replaced, without prejudice to the obligations of the Member States relating to the time limit for subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2014/688/EU.
Denne afgørelse anvendes i overensstemmelse med traktaterne.
Article 3
Udfærdiget i Luxembourg, den 8. oktober 2015.
This Decision shall enter into force on the day following that of its publication in the Official Journal of the European Union.
På Rådets vegne
This Decision shall apply in accordance with the Treaties.
J. Asselborn
Done at Luxembourg, 8 October 2015.
EUT L 127 af 20.5.2005, s. 32.
For the Council
Rådets afgørelse 2003/847/RIA af 27. november 2003 om kontrolforanstaltninger og strafferetlige foranstaltninger med hensyn til de nye former for syntetisk narkotika 2C-I, 2C-T-2, 2C-T-7 og TMA-2 (EUT L 321 af 6.12.2003, s. 64).
The President
Domstolen dom af 16. april 2015, Parlamentet mod Rådet, forenede sager C-317/13 og C-679/13, ECLI:EU:C:2015:223.
OJ L 127, 20.5.2005, p. 32.
Rådets gennemførelsesafgørelse 2014/688/EU af 25. september 2014 om at underkaste 4-iod-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamin (25I-NBOMe), 3,4-dichlor-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamid (AH-7921), 3,4-methylendioxypyrovaleron (MDPV) og 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanon (methoxetamin) kontrolforanstaltninger (EUT L 287 af 1.10.2014, s. 22).
Council Decision 2003/847/JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2 (OJ L 321, 6.12.2003, p. 64).
AH-7921 er et strukturmæssigt atypisk syntetisk opioidt analgetikum, som går under betegnelsen »doxylam« hos forhandlere på internettet, på brugernetsteder og i medierne.
Judgment of the Court of Justice of 16 April 2015, Parliament v Council, Joined Cases C-317/13 and C-679/13, ECLI:EU:C:2015:223.
Det kan let forveksles med »doxylamin«, der er et antihistaminlægemiddel med beroligende-søvndyssende egenskaber, hvilket kan føre til utilsigtet overdosering.
Council Implementing Decision 2014/688/EU of 25 September 2014 on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures (OJ L 287, 1.10.2014, p. 22).
Formand
AH-7921 is a structurally atypical synthetic opioid analgesic commonly known by internet suppliers, user websites and media as ‘doxylam’.
Rådets gennemførelsesafgørelse (EU) 2015/1876
Council Implementing Decision (EU) 2015/1876
I overensstemmelse med artikel 6 i afgørelse 2005/387/RIA udarbejdede det udvidede videnskabelige udvalg under Det Europæiske Overvågningscenter for Narkotika og Narkotikamisbrug (EMCDDA) på et særligt møde en risikovurderingsrapport om det nye psykoaktive stof 5-(2-aminopropyl)indol, som efterfølgende blev forelagt Kommissionen og Rådet den 16. april 2013.
A Risk Assessment Report on the new psychoactive substance 5-(2-aminopropyl)indole was drawn up in accordance with Article 6 of Decision 2005/387/JHA by the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) during a special session, and was subsequently submitted to the Commission and to the Council on 16 April 2013.
Det er vanskeligt at bestemme de specifikke fysiske virkninger af 5-(2-aminopropyl)indol i mennesker, da der ikke er offentliggjort undersøgelser om vurdering af stoffets akutte og kroniske toksicitet, dets virkninger for psyke og adfærd eller dets mulige afhængighedsskabende virkning, og da de foreliggende oplysninger og data er begrænsede.
The existing information and data suggest that the acute toxicity of 5-(2-aminopropyl)indole can provoke adverse effects in humans, such as tachycardia and hyperthermia, and may also cause mydriasis, agitation and tremor.
Der er registreret i alt 24 dødsfald i fire medlemsstater fra april til august 2012, hvor 5-(2-aminopropyl)indol alene eller sammen med andre stoffer blev påvist i obduktionsprøver.
5-(2-aminopropyl)indole may interact with other substances, including medical products and stimulants that act on the monoaminergic system.
Det kan ikke med sikkerhed fastslås, hvilken rolle 5-(2-aminopropyl)indol har spillet i alle disse dødsfald, men i nogle tilfælde er stoffet specifikt nævnt under dødsårsagen.
The specific physical effects of 5-(2-aminopropyl)indole in humans are difficult to determine because there are no published studies assessing its acute and chronic toxicity, its psychological and behavioural effects, or dependence potential, and because of the limited information and data available.
Øget tilgængelighed og mere udbredt anvendelse af dette nye psykoaktive stof kan få betydelige følger for enkeltpersoners sundhed og folkesundheden.
There have been a total of 24 fatalities registered in four Member States from April to August 2012, in relation to which 5-(2-aminopropyl)indole alone, or in combination with other substances, was detected in post-mortem samples.
Der foreligger ingen oplysninger om de sociale risici i forbindelse med 5-(2-aminopropyl)indol.
While it is not possible to determine with certainty the role of 5-(2-aminopropyl)indole in all of the fatalities, in some cases it has been specifically noted in the cause of death.
Ni europæiske lande har indberettet til EMCDDA og til Den Europæiske Politienhed (Europol), at de har fundet 5-(2-aminopropyl)indol.
If this new psychoactive substance were to become more widely available and used, the implications for individual and public health could be significant.
Der foreligger ingen data om, hvor udbredt brugen af 5-(2-aminopropyl)indol er, men de begrænsede oplysninger, der foreligger, tyder på, at stoffet muligvis indtages i samme miljøer som andre opkvikkende midler, f.eks. i hjemmet, i barer og på natklubber eller ved musikfestivaler.
There is no information available on the social risks posed by 5-(2-aminopropyl)indole.
Der er ingen oplysninger, der tyder på, at 5-(2-aminopropyl)indol fremstilles i Unionen, og der findes ikke dokumentation for, at organiseret kriminalitet er involveret i fremstillingen, distributionen eller forsyningen af dette nye psykoaktive stof.
Nine European countries have reported to the EMCDDA and to the European Police Office (Europol) that they reported detection of 5-(2-aminopropyl)indole.
Stoffet 5-(2-aminopropyl)indol har ingen kendt, dokumenteret eller anerkendt medicinsk værdi eller anvendelse, og der er ingen markedsføringstilladelse for dette nye psykoaktive stof i Unionen.
No prevalence data is available on the use of 5-(2-aminopropyl)indole, but the limited information that exists suggests that it may be consumed in similar environments as other stimulants, such as in the home, in bars and nightclubs or at music festivals.
Bortset fra stoffets anvendelse som analysereferencestandard og i videnskabelig forskning er der ingen indikationer på, at det anvendes til andre formål.
There is no information that suggests that 5-(2-aminopropyl)indole is manufactured in the Union, and there is no evidence suggesting the involvement of organised crime in the manufacture, distribution or supply of this new psychoactive substance.
Stoffet 5-(2-aminopropyl)indol er ikke vurderet og ikke i øjeblikket under vurdering i FN-systemet, som defineret i 2005/387/RIA.
The substance 5-(2-aminopropyl)indole has no known, established or acknowledged medical value or use, and there is no marketing authorisation covering this new psychoactive substance in the Union.
Risikovurderingsrapporten viser, at der kun foreligger begrænset videnskabelig dokumentation om 5-(2-aminopropyl)indol, og påpeger, at der er behov for yderligere forskning for at fastslå, hvilke sundhedsrisici og sociale risici der er forbundet med stoffet.
Apart from its use as an analytical reference standard and in scientific research, there is no indication that it is being used for other purposes.
Det materiale og de oplysninger, der foreligger, udgør dog et tilstrækkeligt grundlag til at underkaste 5-(2-aminopropyl)indol kontrolforanstaltninger i hele Unionen.
The substance 5-(2-aminopropyl)indole has not been, nor is it currently, under assessment by the United Nations' system, as defined in Decision 2005/387/JHA.
Eftersom seks medlemsstater allerede benytter lovbestemmelser af forskellig karakter til at føre kontrol med 5-(2-aminopropyl)indol, vil det bidrage til at undgå problemer med grænseoverskridende lovhåndhævelse og retligt samarbejde og beskytte brugerne mod de farer, indtagelse af stoffet kan indebære, hvis stoffet underkastes kontrolforanstaltninger i hele Unionen.
Five European countries apply national legislation on new psychoactive substances, dangerous goods or medicines to control 5-(2-aminopropyl)indole.
Afgørelse 2005/387/RIA tillægger Rådet gennemførelsesbeføjelser for at kunne reagere hurtigt og på grundlag af ekspertise på EU-plan på fremkomsten af nye psykoaktive stoffer, som medlemsstaterne har påvist og indberettet, ved at underkaste disse stoffer kontrolforanstaltninger i hele Unionen.
The Risk Assessment Report reveals that there is limited scientific evidence available on 5-(2-aminopropyl)indole and points out that further research would be needed to determine the health and social risks that it poses.
Da betingelserne og proceduren for at udløse udøvelsen af sådanne gennemførelsesbeføjelser er opfyldt, bør der vedtages en gennemførelsesafgørelse for at underkaste 5-(2-aminopropyl)indol kontrol i hele Unionen.
However, the available evidence and information provides sufficient ground for subjecting 5-(2-aminopropyl)indole to control measures across the Union.
Denne afgørelse erstatter Rådets gennemførelsesafgørelse 2013/496/EU [2], som blev annulleret af Den Europæiske Unions Domstol (»Domstolen«) ved dom af 16. april 2015 i sag C-679/13 [3].
As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use, 5-(2-aminopropyl)indole should be subjected to control measures across the Union.
I denne dom opretholdt Domstolen virkningerne af afgørelse 2013/496/EU, indtil en ny lovgivning træder i kraft som erstatning herfor.
Given that six Member States already control 5-(2-aminopropyl)indole by means of different types of legislative provisions, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and protect users from the risks that its consumption can pose.
Derfor ophører afgørelse 2013/496/EU med at have virkning fra datoen for denne afgørelses ikrafttræden.
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Med henblik på at sikre kontinuiteten af kontrolforanstaltninger i hele Unionen med hensyn til 5-(2-aminopropyl)indol bør denne afgørelse ikke berøre medlemsstaternes forpligtelser med hensyn til fristen for at underkaste nye psykoaktive stoffer kontrolforanstaltninger og strafferetlige sanktioner i deres nationale lovgivning som fastsat i artikel 2 i afgørelse 2013/496/EU.
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 5-(2-aminopropyl)indole under control across the Union.
Afgørelse 2005/387/RIA er bindende for Danmark, som derfor deltager i vedtagelsen og anvendelsen af denne afgørelse, der gennemfører afgørelse 2005/387/RIA.
This Decision replaces Council Implementing Decision 2013/496/EU [2] which was annulled by the Court of Justice of the European Union (‘the Court’) by its judgment of 16 April 2015 in Case C-679/13 [3].
Afgørelse 2005/387/RIA er bindende for Irland, som derfor deltager i vedtagelsen og anvendelsen af denne afgørelse, der gennemfører afgørelse 2005/387/RIA.
In that judgment, the Court maintained the effects of Decision 2013/496/EU until the entry into force of new acts intended to replace it.
Afgørelse 2005/387/RIA er ikke bindende for Det Forenede Kongerige, som derfor ikke deltager i vedtagelsen af denne afgørelse, som gennemfører afgørelse 2005/387/RIA, og som ikke er bindende for og ikke finder anvendelse i Det Forenede Kongerige —
Therefore, as of the day of entry into force of this Decision, Decision 2013/496/EU ceases to produce effects.
VEDTAGET DENNE AFGØRELSE:
In order to ensure the continuity of control measures across the Union with regard to 5-(2-aminopropyl)indole, this Decision should be without prejudice to the obligations of the Member States relating to the time limit for subjecting that new psychoactive substance to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2013/496/EU.
Artikel 1
Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Det nye psykoaktive stof 5-(2-aminopropyl)indol underkastes kontrolforanstaltninger i hele Unionen.
Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Artikel 2
The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision which implements Decision 2005/387/JHA and is not bound by it or subject to its application,
Afgørelse 2013/496/EU ophører med at have virkning fra datoen for nærværende afgørelses ikrafttræden, uden at dette berører medlemsstaternes forpligtelser med hensyn til fristen for at underkaste 5-(2-aminopropyl)indol kontrolforanstaltninger og strafferetlige sanktioner i deres nationale lovgivning som fastsat i artikel 2 i afgørelse 2013/496/EU.
HAS ADOPTED THIS DECISION:
Denne afgørelse træder i kraft dagen efter offentliggørelsen i Den Europæiske Unions Tidende.
The new psychoactive substance 5-(2-aminopropyl)indole shall be subjected to control measures across the Union.
Denne afgørelse anvendes i overensstemmelse med traktaterne.
Article 2
Udfærdiget i Luxembourg, den 8. oktober 2015.
Decision 2013/496/EU ceases to produce effects from the date of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting 5-(2-aminopropyl)indole to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2013/496/EU.
J. Asselborn
This Decision shall enter into force on the day following that of its publication in the Official Journal of the European Union.
EUT L 127 af 20.5.2005, s. 32.
This Decision shall apply in accordance with the Treaties.
Rådets gennemførelsesafgørelse (2013/496/EU) af 7. oktober 2013 om at underkaste 5-(2-aminopropyl)indol kontrolforanstaltninger (EUT L 272 af 12.10.2013, s. 44).
Done at Luxembourg, 8 October 2015.
Domstolens dom af 16. april 2015, Parlamentet mod Rådet, C-679/13, ECLI:EU:C:2015:223.
For the Council
To medlemsstater fører kontrol med dette nye psykoaktive stof i henhold til deres nationale lovgivning som følge af deres forpligtelser i henhold til FN's konvention af 1971 om psykotrope stoffer.
The President
Fem europæiske lande anvender national lovgivning om nye psykoaktive stoffer, farligt gods eller medicin til at føre kontrol med 5-(2-aminopropyl)indol.
OJ L 127, 20.5.2005, p.
Stoffet kan købes på internettet og i »hampeforretninger«, idet det markedsføres som et »forskningskemikalie«.
32.
Stoffet er også påvist i et produkt med betegnelsen »Benzo Fury«, der er solgt som et »legalt rusmiddel«, og i tabletter, der ligner ecstasy.
Council Implementing Decision (2013/496/EU) of 7 October 2013 on subjecting 5-(2-aminopropyl)indole to control measures (OJ L 272, 12.10.2013, p.
Formand
44).
Kommissionens afgørelse (EU) 2015/1877
Commission Decision (EU) 2015/1877
om de takster S.C.
on tariffs charged by S.C.
Hidroelectrica S.A., Rumænien, anvender over for S.C.
Hidroelectrica SA of Romania to S.C.
Termoelectrica S.A. og S.C.
Termoelectrica SA and S.C.
Electrocentrale Deva S.A. — SA.33475 (12/C)
Electrocentrale Deva SA — SA.33475 (12/C)
(meddelt under nummer C(2015) 2648)
(notified under document number C(2015) 2648)
under henvisning til Kommissionens afgørelse om at indlede proceduren efter traktatens artikel 108, stk. 2, i statsstøttesag SA.33475 (12/C, ex 12/NN) [1],
Having regard to the decision by which the Commission initiated the procedure laid down in Article 108(2) of the Treaty, in respect of the aid SA.33475 (12/C, ex 12/NN) [1],
efter i henhold til ovennævnte bestemmelser at have opfordret interesserede parter til at fremsætte bemærkninger, under henvisning til disse bemærkninger, og
Having called on third parties to submit their comments pursuant to the provisions cited above, and having regard to their comments,
Den 2. august 2011 modtog Kommissionen en klage fra investeringsfonden S.C.
On 2 August 2011, the Commission received a complaint from the investment fund S.C.
Fondul Proprietatea S.A. (»klageren«) over S.C.
Fondul Proprietatea SA (‘the complainant’) in relation to the purchase of electricity by S.C.
Hidroelectrica S.A.s (»Hidroelectrica«) køb af elektricitet fra elleverandører til priser, der angiveligt var højere end markedsprisen.
Hidroelectrica SA (‘Hidroelectrica’) from electricity suppliers at prices allegedly set above market level.
Ved brev af 25. april 2012 meddelte Kommissionen Rumænien, at den havde besluttet at indlede proceduren efter traktatens artikel 108, stk. 2, med hensyn til de kontrakter, hvorunder Termoelectrica S.A. (»Termoelectrica«) og S.C.
On 25 April 2012, the Commission informed Romania that it had decided to initiate the procedure laid down in Article 108(2) of the Treaty in respect of the contracts whereby Termoelectrica SA (‘Termoelectrica’) and S.C.
Electrocentrale Deva S.A. (»Electrocentrale Deva«) leverede elektricitet engros til Hidroelectrica, i det følgende benævnt »åbningsafgørelsen«.
Electrocentrale Deva SA (‘Electrocentrale Deva’) supplied electricity wholesale to Hidroelectrica, hereafter referred as the ‘Opening Decision’.